<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">cc8157</article-id><article-id pub-id-type="pmid">19891773</article-id><article-id pub-id-type="doi">10.1186/cc8157</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association of mannose-binding lectin-2 genotype and serum levels with prognosis of sepsis</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Huh</surname><given-names>Jin Won</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jwhuh@paik.ac.kr</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Song</surname><given-names>Kyuyoung</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kysong@amc.seoul.kr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Yum</surname><given-names>Jung-Sun</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jsyum@dobeel.co.kr</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Hong</surname><given-names>Sang-Bum</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>sbhong@amc.seoul.kr</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Lim</surname><given-names>Chae-Man</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>cmlim@amc.seoul.kr</email></contrib><contrib contrib-type="author" corresp="yes" id="A6"><name><surname>Koh</surname><given-names>Younsuck</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>yskoh@amc.seoul.kr</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pulmonary and Critical Care Medicine, Inje University Ilsan Paik Hospital, 2240 Daehwa-dong, Goyang-si, 411-706, Korea</aff><aff id="I2"><label>2</label>Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Seoul, 138-736, Korea</aff><aff id="I3"><label>3</label>Dobeel Corporation, Byoksan Techonopia 407, 434-6 Sandaewon-dong, Seongnam-si, 462-716, Korea</aff><aff id="I4"><label>4</label>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Seoul, 138-736, Korea</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2009</year></pub-date><volume>13</volume><issue>6</issue><fpage>R176</fpage><lpage>R176</lpage><history><date date-type="received"><day>27</day><month>6</month><year>2009</year></date><date date-type="rev-request"><day>1</day><month>8</month><year>2009</year></date><date date-type="rev-recd"><day>30</day><month>8</month><year>2009</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Huh et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Huh et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/13/6/R176"/><abstract><sec><title>Introduction</title><p>Individuals deficient in mannose-binding lectin (MBL), an important component of the innate immune system, show increased susceptibility to infection. We investigated whether polymorphisms in the MBL2 gene and the serum level are associated with the severity and prognosis of sepsis.</p></sec><sec><title>Methods</title><p>A total of 266 patients with sepsis and 398 healthy controls were enrolled. We analyzed the three single nucleotide polymorphisms (Gly54Asp, -550, and +4) in the MBL2 gene. Serum samples collected on day 1 were analyzed for the levels of MBL.</p></sec><sec><title>Results</title><p>Patients who were heterozygous (A/B) or homozygous (B/B) at codon 54 (adjusted odds ratio (OR), 0.370; 95% confidence interval (CI), 0.207-0.661, <italic>P </italic>= 0.001) and who were heterozygous (H/L) or homozygous (L/L) at -550 (adjusted OR, 0.476; 95% CI, 0.249-0.910, <italic>P </italic>= 0.025) were less likely to have septic shock in the sepsis group. Using Cox regression analysis for 28-day mortality, an MBL level &#x02265; 1.3 microg/mL showed significantly lower 28-day mortality (<italic>P </italic>= 0.020; hazard ratio, 0.571; 95% CI, 0.355-0.916) in the septic shock group.</p></sec><sec><title>Conclusions</title><p>Homozygosity at codons 54 (A/A) and -550 (H/H) appears to be associated with the severity, but not the outcome, of sepsis, whereas a low MBL level may be an independent risk factor for mortality. These findings suggest that the genotype and serum level for MBL2 may have different clinical implications.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Severe sepsis and septic shock cause 30% to 50% of all deaths in intensive care units (ICUs) [<xref ref-type="bibr" rid="B1">1</xref>]. Numerous studies have suggested that individuals vary in their ability to resist infection [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Genetic variations, such as those in the <italic>TNF-&#x003b1; </italic>alleles, have been implicated in determining the susceptibility to and outcome of sepsis [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. The innate immune system is activated prior to the acquired immune system, and is thus the first line of defense against pathogens. The importance of the interactions between pathogen-associated microbial patterns and mannose-binding lectin (MBL) in activating innate immunity has been considered as a component of the innate immune system [<xref ref-type="bibr" rid="B9">9</xref>]. Moreover, it is now recognized that the first response to invasion (i.e., innate immunity) has a significant influence on the subsequent adaptive response [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>].</p><p>MBL is a calcium-dependent collagenous lectin present in serum. The high-molecular-weight oligomeric form of MBL binds carbohydrates on the surface of bacteria, fungi, and parasites. MBL then mediates activation of the complement cascade through MBL-associated serine proteases (MASP)-1 and -2, resulting in the destruction of microorganisms by opsonization and direct complement-mediated death [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>].</p><p>It has been reported that low concentrations of MBL cause defects in opsonization and phagocytosis that have been associated with recurrent infections in both infants and adults [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Low serum levels of MBL have been correlated with polymorphisms in the protein-coding region of <italic>MBL</italic>2 at codons 52, 54, and 57, which encode the variant alleles D, B, and C, respectively [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. It was previously reported that two <italic>MBL2 </italic>polymorphisms (MBL-2 exon 1 and promoter -221) were associated with the development of sepsis, severe sepsis, and septic shock in Caucasian adults [<xref ref-type="bibr" rid="B21">21</xref>]. However, ethnic differences have been reported for both the promoter and structural variants, and large inter-individual variations in the level of MBL can be explained by the promoter variants [<xref ref-type="bibr" rid="B22">22</xref>]. Among Koreans, no polymorphisms in codons 52 and 57 have been reported, whereas polymorphisms in <italic>MBL</italic>2 at codons 54, -550 (promoter), and +4 (5'-UTR) have been associated with low MBL levels [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>In this study, we investigated the relation between polymorphisms in <italic>MBL</italic>2 and the serum concentration of MBL, and assessed whether these polymorphisms influence the severity and prognosis of sepsis in a Korean population.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Study population</title><p>Two hundred and sixty-six patients receiving intensive care for sepsis between 1 May, 2004 and 31 December, 2006 were enrolled in this study. All patients were managed according to our sepsis management protocol, which was guided by three full-time critical care physicians. All patients were older than 16 years of age (mean age &#x000b1; standard deviation, 61.6 &#x000b1; 14.7 years; male:female (M:F) = 169:97) and had been admitted to the ICU of a university-affiliated hospital in Seoul, Korea. The patients were divided into two groups: the severe sepsis group (mean age 61.6 &#x000b1; 16.9 years; M:F = 45:32) and the septic shock group (mean age 61.6 &#x000b1; 13.8 years; M:F = 124:65). The diagnosis of severe sepsis or septic shock was based on the criteria presented at the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference in 1992 [see Additional data file <xref ref-type="supplementary-material" rid="S1">1</xref>] [<xref ref-type="bibr" rid="B24">24</xref>]. As control subjects, 398 healthy blood donors (mean age 37.2 &#x000b1; 14.2 years; M:F = 219:179) were recruited. Informed consent was obtained from all study participants in accordance with the policies of the Institutional Review Board. This study was approved by the Institutional Review Board of the Asan Medical Center, Seoul, Korea.</p><p>Clinical data, including demographic details, the Sequential Organ Failure Assessment (SOFA) score, the Acute Physiology, Age, and Chronic Health Evaluation II (APACHE II) score obtained at day one of severe sepsis or septic shock, and the ICU outcome, were recorded for each patient. Blood samples for MBL polymorphism and serum level were drawn within 24 hours of the onset of severe sepsis or septic shock</p></sec><sec><title>Single nucleotide polymorphism genotyping</title><p>We chose three single nucleotide polymorphism (SNPs; -550 in the promoter, +4 in the upstream region, and Gly54Asp in the coding region), which had previously exhibited an association with low MBL levels [<xref ref-type="bibr" rid="B23">23</xref>]. Genotyping was performed by PCR and sequencing, as previously described [<xref ref-type="bibr" rid="B25">25</xref>]. Haplotype analysis (<italic>A/B </italic>at codon 54, <italic>H/L </italic>at -550, and <italic>P/Q </italic>at +4) was performed to characterize the combined effects of the polymorphisms [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>The polymorphism of -550 in the promoter was amplified by PCR in a 302 bp fragment: forward primer 5'-TTGCCAGTGGTTTTTGACTC-3' and reverse primer 5'-GTATCTGGGCAGCTGATTCC-3'. The two polymorphisms of +4 in the upstream region and Gly54Asp were amplified by PCR in a 386 bp fragment: forward primer 5'-AGTCACGCAGTGTCACAAGG-3' and reverse primer 5'-AGAACAGCCCAACACGTACC-3'.</p></sec><sec><title>Quantification of MBL by double antibody sandwich ELISA</title><p>The serum MBL level was measured using a sandwich ELISA (MBL-ELISA; Dobeel, Gyeonggi, Korea) according to a previously established protocol [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>Statistical analysis</title><p>The descriptive results of the continuous variables were expressed as medians with an interquartile range (IQR). All categorical data were compared using chi-squared analysis or a Fisher's exact test. Continuous data were compared using the Kruskal-Wallis or Mann-Whitney U tests. A receiver operating characteristic (ROC) curve was used to evaluate the cut-off values for the MBL level. A multiple stepwise logistic regression model was used to evaluate the prognostic value of the MBL level. The genotype frequencies were checked for consistency among cases and controls separately with those expected from the Hardy-Weinberg equilibrium [see Additional data file <xref ref-type="supplementary-material" rid="S2">2</xref>] using commercial software (SNP Alyze v 5.0; Dynacom, Yokohama, Japan). The association between cases and controls were examined by comparing allele and genotype frequencies in different groups of subjects using a chi-squared test. Allelic frequencies were compared between cases and controls using logistic regression to calculate age, gender-adjusted odds ratios (OR), and 95% confidence intervals (CI). Logistic regression analysis was also conducted to examine any significant association between polymorphism and disease phenotype (disease site and behavior). The pairwise linkage disequilibrium (LD) values, D', <italic>R</italic><sup>2</sup>, and <italic>P </italic>values corresponding to chi-squared tests were calculated using the SNP Alyze software package (SNP Alyze v 5.0; Dynacom, Yokohama, Japan). The same software was used to estimate haplotypes and their frequencies. SNP Alyze software uses an expectation-maximization algorithm that determines the maximum-likelihood frequencies of multi-locus haplotypes in diploid populations. To examine differences in individual haplotype frequency and overall haplotype profiles between cases and controls, a permutation test was performed using the SNP Alyze software. In addition, <italic>P </italic>values were calculated by chi-squared statistics derived from simple two by two tables based on the frequency of each haplotype versus all others combined between cases and controls.</p></sec></sec><sec><title>Results</title><sec><title>Demographics of the subjects</title><p>The characteristics of the patients at the time of admission are shown in Table <xref ref-type="table" rid="T1">1</xref>. The overall mortality rate at 28 days was 31.4%. The severe sepsis group had a lower SOFA score and lower mortality rate compared with the septic shock group (10.6% vs. 39.7%; <italic>P </italic>&#x0003c; 0.001).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the patients at day one of severe sepsis or septic shock</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="center">Severe sepsis<break/>(n = 77)</th><th align="center">Septic shock<break/>(n = 189)</th><th align="center"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left">Age</td><td align="center">65 (57-71)</td><td align="center">65 (53-71)</td><td align="center">NS</td></tr><tr><td align="left">Male gender, %</td><td align="center">58.4</td><td align="center">65.6</td><td align="center">NS</td></tr><tr><td align="left">APACHE II score</td><td align="center">19 (15-24)</td><td align="center">26 (21-34)</td><td align="center">0.000</td></tr><tr><td align="left">SOFA score</td><td align="center">9 (7-11)</td><td align="center">13 (10-15)</td><td align="center">0.000</td></tr><tr><td align="left">Admission route, n (%)</td><td/><td/><td align="center">NS</td></tr><tr><td align="left">Medical</td><td align="center">73 (94.8)</td><td align="center">167 (88.4)</td><td/></tr><tr><td align="left">Surgical</td><td/><td/><td/></tr><tr><td align="left">elective/emergent</td><td align="center">3 (3.9)/1 (1.3)</td><td align="center">18 (9.5)/4 (2.1)</td><td/></tr><tr><td align="left">Prior or preexisting disease, n (%)</td><td/><td/><td align="center">NS</td></tr><tr><td align="left">Chronic liver disease</td><td align="center">6 (7.8)</td><td align="center">17 (9.0)</td><td/></tr><tr><td align="left">Chronic pulmonary disease</td><td align="center">1 (1.3)</td><td align="center">7 (3.7)</td><td/></tr><tr><td align="left">Congestive heart disease</td><td align="center">2 (2.6)</td><td align="center">4 (2.1)</td><td/></tr><tr><td align="left">Diabetes mellitus</td><td/><td align="center">5 (2.6)</td><td/></tr><tr><td align="left">Malignancy</td><td align="center">14 (18.2)</td><td align="center">44 (23.3)</td><td/></tr><tr><td align="left">Neurologic disease</td><td align="center">5 (6.5)</td><td align="center">10 (5.3)</td><td/></tr><tr><td align="left">Others<sup>a</sup></td><td align="center">3 (3.9)</td><td align="center">7 (3.7)</td><td/></tr><tr><td align="left">&#x02265; 2 diseases</td><td align="center">7 (9.1)</td><td align="center">22 (11.6)</td><td/></tr><tr><td align="left">None</td><td align="center">39 (50.7)</td><td align="center">73 (38.6)</td><td/></tr><tr><td align="left">Type of infection, n (%)</td><td/><td/><td align="center">0.034</td></tr><tr><td align="left">Pneumonia</td><td align="center">20 (26.0)</td><td align="center">80 (42.3)</td><td/></tr><tr><td align="left">Intraabdominal infection</td><td align="center">15 (19.5)</td><td align="center">34 (18.0)</td><td/></tr><tr><td align="left">Biliary</td><td align="center">20 (26.0)</td><td align="center">19 (10.1)</td><td/></tr><tr><td align="left">Urinary tract infection</td><td align="center">11 (14.3)</td><td align="center">21 (11.1)</td><td/></tr><tr><td align="left">Bacteremia</td><td align="center">2 (2.6)</td><td align="center">4 (2.1)</td><td/></tr><tr><td align="left">Wound infection</td><td align="center">5(6.5)</td><td align="center">12 (6.3)</td><td/></tr><tr><td align="left">Others<sup>b</sup></td><td align="center">4 (5.2)</td><td align="center">19 (10)</td><td/></tr><tr><td align="left">Positive culture, n (%)</td><td align="center">45.5</td><td align="center">37.0</td><td align="center">NS</td></tr><tr><td align="left">Gram-negative</td><td align="center">68.6</td><td align="center">60.0</td><td/></tr><tr><td align="left">Gram-positive</td><td align="center">17.1</td><td align="center">31.4</td><td/></tr><tr><td align="left">Mixed</td><td align="center">11.4</td><td align="center">2.9</td><td/></tr><tr><td align="left">Anaerobe</td><td align="center">2.9</td><td align="center">2.9</td><td/></tr><tr><td align="left">Fungi</td><td/><td align="center">2.9</td><td/></tr><tr><td align="left">Mechanical ventilation, %</td><td align="center">51.9</td><td align="center">79.3</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">Renal replacement, %</td><td align="center">9.1</td><td align="center">31.2</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">Length of ICU stay, days</td><td align="center">4 (3-9)</td><td align="center">10 (6-19)</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">Nosocomial infection, %</td><td align="center">23.4</td><td align="center">22.2</td><td align="center">NS</td></tr></tbody></table><table-wrap-foot><p>Data are presented as the median and interquartile range (25% to 75%). <sup>a </sup>= rheumatologic disease, inflammatory bowel disease; <sup>b </sup>= cellulitis, meningitis, leptospirosis.</p><p>APACHE II = Acute Physiology, Age, and Chronic Health Evaluation II; ICU = intensive care unit; NS = not significant; SOFA = Sequential Organ Failure Assessment.</p></table-wrap-foot></table-wrap></sec><sec><title>The association of the MBL2 gene polymorphisms with sepsis susceptibility</title><p>Patients who were heterozygous (<italic>A/B</italic>) or homozygous (<italic>B/B</italic>) for the polymorphism at codon 54 (adjusted OR, 0.370; 95% CI, 0.207 to 0.661, <italic>P </italic>= 0.001) were less likely to have septic shock in the sepsis group (Table <xref ref-type="table" rid="T2">2</xref>). Those patients in the sepsis group who were heterozygous (<italic>H/L</italic>) or homozygous (<italic>L/L</italic>) at -550 (adjusted OR, 0.476; 95% CI, 0.249 to 0.910, <italic>P </italic>= 0.025) were less likely to have septic shock (Table <xref ref-type="table" rid="T3">3</xref>). The frequencies of <italic>P/Q </italic>at +4 were not significantly different among the three groups (data not shown).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Genotype frequencies for Gly54Asp in mannose-binding lectin between patients and controls and between septic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center">Locus</th><th align="center">Allele</th><th align="center" colspan="2">Group<break/>N (%)</th><th align="center" colspan="2">Group<break/>n (%)</th><th align="center">OR<break/>(95% CI)</th><th align="center"><italic>P</italic></th><th align="center">Adjusted OR<sup>a</sup><break/>(95% CI)</th><th align="center"><italic>P</italic></th></tr></thead><tbody><tr><td/><td/><td align="center" colspan="2">Sepsis</td><td align="center" colspan="2">Control</td><td/><td/><td/><td/></tr><tr><td align="center">GG</td><td align="center">A</td><td align="center">185</td><td align="center">72.27</td><td align="center">262</td><td align="center">66.16</td><td/><td/><td/><td/></tr><tr><td align="center">GA</td><td/><td align="center">64</td><td align="center">25.00</td><td align="center">115</td><td align="center">29.04</td><td align="center">0.788<break/>(0.550, 1.129)</td><td align="center">0.194</td><td align="center">0.815<break/>(0.507, 1.312)</td><td align="center">0.400</td></tr><tr><td align="center">AA</td><td align="center">B</td><td align="center">7</td><td align="center">2.73</td><td align="center">19</td><td align="center">4.80</td><td align="center">0.522<break/>(0.215, 1.266)</td><td align="center">0.150</td><td align="center">0.388<break/>(0.127, 1.180)</td><td align="center">0.095</td></tr><tr><td align="center">GG</td><td/><td align="center">185</td><td align="center">72.27</td><td align="center">262</td><td align="center">66.16</td><td/><td/><td/><td/></tr><tr><td align="center">GA/AA</td><td/><td align="center">71</td><td align="center">27.73</td><td align="center">134</td><td align="center">33.84</td><td align="center">0.750<break/>(0.532, 1.058)</td><td align="center">0.102</td><td align="center">0.742<break/>(0.471, 1.167)</td><td align="center">0.196</td></tr><tr><td/><td/><td align="center" colspan="2">Septic shock</td><td align="center" colspan="2">Severe sepsis</td><td/><td/><td/><td/></tr><tr><td align="center">GG</td><td align="center">A</td><td align="center">144</td><td align="center">77.84</td><td align="center">41</td><td align="center">57.75</td><td/><td/><td/><td/></tr><tr><td align="center">GA</td><td/><td align="center">37</td><td align="center">20.00</td><td align="center">27</td><td align="center">38.03</td><td align="center">0.362<break/>(0.199, 0.658)</td><td align="center">0.001</td><td align="center">0.368<break/>(0.202, 0.672)</td><td align="center">0.001</td></tr><tr><td align="center">AA</td><td align="center">B</td><td align="center">4</td><td align="center">2.16</td><td align="center">3</td><td align="center">4.23</td><td align="center">0.389<break/>(0.084, 1.807)</td><td align="center">0.228</td><td align="center">0.381<break/>(0.081, 1.794)</td><td align="center">0.222</td></tr><tr><td align="center">GG</td><td/><td align="center">144</td><td align="center">77.84%</td><td align="center">41</td><td align="center">57.75%</td><td/><td/><td/><td/></tr><tr><td align="center">GA/AA</td><td/><td align="center">41</td><td align="center">22.16%</td><td align="center">30</td><td align="center">42.25%</td><td align="center">0.365<break/>(0.205, 0.650)</td><td align="center">0.001</td><td align="center">0.370<break/>(0.207, 0.661)</td><td align="center">0.001</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>= The adjusted OR was adjusted for age and gender. CI = confidence interval; OR = odds ratio.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Genotype frequencies for --550 in mannose-binding lectin between patients and controls and between septic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center">Locus</th><th align="center">Allele</th><th align="center" colspan="2">Group<break/>n (%)</th><th align="center" colspan="2">Group<break/>n (%)</th><th align="center">OR<break/>(95% CI)</th><th align="center"><italic>P</italic></th><th align="center">Adjusted OR<sup>a</sup><break/>(95% CI)</th><th align="center"><italic>P</italic></th></tr></thead><tbody><tr><td/><td/><td align="center" colspan="2">Sepsis</td><td align="center" colspan="2">Control</td><td/><td/><td/><td/></tr><tr><td align="center">GG</td><td align="center">H</td><td align="center">77</td><td align="center">30.20</td><td align="center">124</td><td align="center">31.16</td><td/><td/><td/><td/></tr><tr><td align="center">GC</td><td/><td align="center">122</td><td align="center">47.84</td><td align="center">182</td><td align="center">45.73</td><td align="center">1.079<break/>(0.749, 1.556)</td><td align="center">0.682</td><td align="center">1.060<break/>(0.783, 3.598)</td><td align="center">0.810</td></tr><tr><td align="center">CC</td><td align="center">L</td><td align="center">56</td><td align="center">21.96</td><td align="center">92</td><td align="center">23.12</td><td align="center">0.980<break/>(0.633, 1.518)</td><td align="center">0.929</td><td align="center">1.333<break/>(0.755, 2.355)</td><td align="center">0.322</td></tr><tr><td align="center">GG</td><td/><td align="center">77</td><td align="center">30.20</td><td align="center">124</td><td align="center">31.16</td><td/><td/><td/><td/></tr><tr><td align="center">GC/CC</td><td/><td align="center">178</td><td align="center">69.80</td><td align="center">274</td><td align="center">68.84</td><td align="center">1.046<break/>(0.744, 1.472)</td><td align="center">0.795</td><td align="center">1.142<break/>(0.734, 1.788)</td><td align="center">0.555</td></tr><tr><td/><td/><td align="center" colspan="2">Septic shock</td><td align="center" colspan="2">Severe sepsis</td><td/><td/><td/><td/></tr><tr><td align="center">GG</td><td align="center">H</td><td align="center">63</td><td align="center">34.24</td><td align="center">14</td><td align="center">19.72</td><td/><td/><td/><td/></tr><tr><td align="center">GC</td><td/><td align="center">85</td><td align="center">46.20</td><td align="center">37</td><td align="center">52.11</td><td align="center">0.479<break/>(0.239, 0.957)</td><td align="center">0.037</td><td align="center">0.465<break/>(0.231, 0.936)</td><td align="center">0.032</td></tr><tr><td align="center">CC</td><td align="center">L</td><td align="center">36</td><td align="center">19.57</td><td align="center">20</td><td align="center">28.17</td><td align="center">0.381<break/>(0.173, 0.840)</td><td align="center">0.017</td><td align="center">0.379<break/>(0.171, 0.839)</td><td align="center">0.017</td></tr><tr><td align="center">GG</td><td/><td align="center">63</td><td align="center">34.24</td><td align="center">14</td><td align="center">19.72</td><td/><td/><td/><td/></tr><tr><td align="center">GC/CC</td><td/><td align="center">121</td><td align="center">65.76</td><td align="center">57</td><td align="center">80.28</td><td align="center">0.484<break/>(0.254, 0.922)</td><td align="center">0.027</td><td align="center">0.476<break/>(0.249, 0.910)</td><td align="center">0.025</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>= The adjusted OR was adjusted for age and gender. CI = confidence interval; OR = odds ratio.</p></table-wrap-foot></table-wrap></sec><sec><title>The association of serum MBL levels with the MBL2 genotypes</title><p>The distribution of MBL concentrations was closely associated with the various <italic>MBL2 </italic>genotypes. The <italic>HH, HL</italic>, and <italic>LL </italic>genotypes of the -550 polymorphism and the <italic>AA, AB</italic>, and <italic>BB </italic>genotypes of the codon 54 polymorphism were correlated with high, medium, and low MBL levels, respectively, in all three groups, whereas the <italic>QQ, PQ</italic>, and <italic>PP </italic>genotypes of the +4 polymorphism were correlated with high, medium, and low MBL levels, respectively, only in the control group (Table <xref ref-type="table" rid="T4">4</xref>). The serum MBL level was different among the three groups, even for subjects with the same genotype. Among the subjects with genotype <italic>HL/LL </italic>at -550 and <italic>PP </italic>at +4, the serum MBL level was higher for those in the septic shock group than for those in the severe sepsis group (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Correlation of SNPs in the <italic>mbl2 </italic>gene with the serum MBL level</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th/><th align="center" colspan="2">Normal control</th><th align="center" colspan="2">Severe sepsis</th><th align="center" colspan="2">Septic shock</th></tr><tr><th/><th/><th/><th colspan="6"><hr/></th></tr><tr><th align="left">Loci</th><th align="center">Allele</th><th align="center">Genotype</th><th align="center">Median<break/>(IQR)<break/>&#x003bc;g/L</th><th align="center"><italic>P</italic><sup>a</sup></th><th align="center">Median<break/>(IQR)<break/>&#x003bc;g/L</th><th align="center"><italic>P</italic><sup>a</sup></th><th align="center">Median<break/>(IQR)<break/>&#x003bc;g/L</th><th align="center"><italic>P</italic><sup>a</sup></th></tr></thead><tbody><tr><td align="left">-550</td><td align="left">H</td><td align="center">GG</td><td align="center">2493<break/>(1452--3992)</td><td align="center">0.000</td><td align="center">2250<break/>(1285--4800)</td><td align="center">0.000</td><td align="center">2550<break/>(2010--3945)</td><td align="center">0.000</td></tr><tr><td/><td/><td align="center">GC</td><td align="center">955<break/>(335--2626)</td><td/><td align="center">810<break/>(600--1360)</td><td/><td align="center">1530<sup>bc</sup><break/>(860--2400)</td><td/></tr><tr><td/><td align="left">L</td><td align="center">CC</td><td align="center">384<break/>(0--1284)</td><td/><td align="center">340<break/>(275--710)</td><td/><td align="center">640<sup>c</sup><break/>(300--1630)</td><td/></tr><tr><td align="left">Gly54<break/>Asp</td><td align="left">A</td><td align="center">GG</td><td align="center">2249<break/>(1333--3352)</td><td align="center">0.000</td><td align="center">1370<break/>(825--3925)</td><td align="center">0.000</td><td align="center">2280<break/>(1500--2800)</td><td align="center">0.000</td></tr><tr><td/><td/><td align="center">GA</td><td align="center">315<break/>(3--540)</td><td/><td align="center">460<sup>b</sup><break/>(335--695)</td><td/><td align="center">475<sup>b</sup><break/>(298--695)</td><td/></tr><tr><td/><td align="left">B</td><td align="center">AA</td><td align="center">0</td><td/><td align="center">270<break/>(135-280)</td><td/><td align="center">270</td><td/></tr><tr><td align="left">+4</td><td align="left">P</td><td align="center">CC</td><td align="center">1039<break/>(215--2668)</td><td align="center">0.036</td><td align="center">800<break/>(430--1363)</td><td align="center">0.367</td><td align="center">1910<sup>bc</sup><break/>(1045--2635)</td><td align="center">0.470</td></tr><tr><td/><td/><td align="center">CT</td><td align="center">2182<break/>(1187--2826)</td><td/><td align="center">800<break/>(370--4265)</td><td/><td align="center">1605<break/>(488--3013)</td><td/></tr><tr><td/><td align="left">Q</td><td align="center">TT</td><td align="center">4823</td><td/><td align="center">2895<break/>(830--4960)</td><td/><td align="center">3570</td><td/></tr></tbody></table><table-wrap-foot><p>Data are expressed as the median and interquartile range (IQR; 25% to 75%). <sup>a </sup>= <italic>P</italic>-value based on the Kruskal--Wallis or Mann--Whitney U test. Statistical differences in the mannose-binding lectin (MBL) levels were analyzed according to genotype within each subgroup. <sup>b </sup>= <italic>P </italic>&#x0003c; 0.05 vs. the control group. <sup>c </sup>= <italic>P </italic>&#x0003c; 0.05 vs. the severe sepsis group. SNP = single nucleotide polymorphism.</p></table-wrap-foot></table-wrap><p>We next analyzed the haplotype profiles to characterize the combined effects of the three polymorphisms. <italic>HPA/HPA</italic>, <italic>HPA/LPA</italic>, and <italic>HPA/LQA </italic>were high MBL-producing haplotypes, and their frequencies were similar among the three groups. For subjects with the <italic>HPA/LPA </italic>haplotype, the serum MBL level was higher for those in the septic shock group than for those in the severe sepsis group (<italic>P </italic>&#x0003c; 0.05). The serum MBL level in the control group was higher than the severe sepsis group for subjects with the <italic>HPA/LPA </italic>or <italic>LPA/LQA </italic>haplotypes (<italic>P </italic>&#x0003c; 0.05) and lower than the severe sepsis group for subjects with the <italic>HPA/LPB </italic>haplotype (<italic>P </italic>&#x0003c; 0.05) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Comparison of serum MBL levels in various haplotypes in the three groups. The serum MBL level in the severe sepsis group was lower than the control group or the septic shock group (<italic>P </italic>&#x0003c; 0.05) for subjects with the <italic>HPA/LPA </italic>haplotype (a). The serum MBL level in the control group was lower than the severe sepsis group (<italic>P </italic>&#x0003c; 0.05) for subjects with the <italic>HPA/LPB </italic>haplotype (b) and higher than the severe sepsis group for subjects with the <italic>LPA/LQA </italic>haplotypes (c). Haplotype estimation was performed using Arlequin software. The median mannose-binding lectin (MBL) levels are indicated by horizontal bars. * <italic>P </italic>&#x0003c; 0.05 between the two groups.</p></caption><graphic xlink:href="cc8157-1"/></fig></sec><sec><title>The association of serum MBL levels with outcome</title><p>The serum MBL level in the septic shock group (1.85 &#x003bc;g/mL; IQR, 0.87 to 2.67) was higher (<italic>P </italic>&#x0003c; 0.05) than the severe sepsis (0.78 &#x003bc;g/mL; IQR, 0.39 to 1.37) or control groups (1.36 &#x003bc;g/mL; IQR, 0.39 to 2.74); however, the serum MBL level was not significantly different between the severe sepsis and control groups. Subgroup analysis of the septic shock group indicated that the survivors in this group (2.18 &#x003bc;g/mL; IQR, 1.15 to 2.95) had a higher serum MBL level (<italic>P </italic>&#x0003c; 0.05) than the non-survivors (1.37 &#x003bc;g/mL; IQR, 0.49 to 2.05) (Figure 2). We divided the septic patients into two groups according to serum MBL levels (MBL &#x0003c;1.3 &#x003bc;g/mL and MBL &#x02265; 1.3 &#x003bc;g/mL) using a ROC curve. There was no difference in frequency for Gram-positive or Gram-negative infection depending on the MBL deficiency. According to the Cox proportional hazards model, a low MBL level (&#x0003c;1.3 &#x003bc;g/mL) was an independent risk factor for mortality after 28 days within the septic shock group (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>The serum MBL levels in the control group and in the patients with severe sepsis and septic shock. The serum mannose-binding lectin (MBL) level in the septic shock group was higher than the severe sepsis or control group. The survivors had a higher serum MBL level than the nonsurvivors in the septic shock group. Data are expressed as the median and interquartile range (IQR). The box represents the median and IQR (25% to 75%) and the error bar represents the IQR (10% to 90%).</p></caption><graphic xlink:href="cc8157-2"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Kaplan-Meier survival curve for septic patients at 28 days according to the MBL level. (a) The difference for 28-day mortality was not found in all patients according to serum MBL levels (MBL &#x0003c;1.3 &#x003bc;g/mL and MBL &#x02265; 1.3 &#x003bc;g/mL). (b) In subgroup analysis, the difference for 28-day mortality within septic shock patients was more pronounced (<italic>P </italic>= 0.020). A low MBL level (&#x0003c;1.3 &#x003bc;g/mL) was an independent risk factor for mortality after 28 days within the septic shock group. There was a hazard ratio of 0.571 (95% confidence interval, 0.355 to 0.916; <italic>P </italic>= 0.020) in the Cox proportional hazards model correcting for age, sex, and comorbidities. MBL = mannose-binding lectin.</p></caption><graphic xlink:href="cc8157-3"/></fig></sec></sec><sec><title>Discussion</title><p>Our study shows that two polymorphisms in <italic>MBL2 </italic>(at codons 54 in exon 1 and -550 in the promoter) may be associated with the severity of sepsis in Korean patients; however, these polymorphisms were not associated with mortality. The serum MBL level was associated with increased risk for mortality after 28 days in the patients with septic shock as found in previous studies [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. However, the serum MBL level was not determined through the known polymorphisms of MBL in the septic condition.</p><p>MBL deficiency has been associated with infections in infants and in patients with concomitant immunodeficiencies [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Recent studies have reported that the frequency of MBL-variant alleles is increased with the severity of sepsis [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. The functionality of the MBL-2 exon 1 and promoter polymorphisms at -221 G/C, termed <italic>Y/X</italic>, has been well documented in Caucasian patients [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. To examine the importance of MBL-variant alleles in the susceptibility to sepsis among Korean patients, we analyzed three polymorphisms (-550, Gly54Asp, and +4) that had previously exhibited significant correlations with the serum MBL level [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>In the present study, the genotypes of individual SNPs were not independently associated with the development of sepsis. However, homozygosity for the <italic>MBL2 </italic>structural genotype (<italic>A/A</italic>) and the -550 genotype (<italic>H/H</italic>) was associated with the progression from severe sepsis to septic shock. Due to selective pressure promoting heterozygosity, a heterozygous advantage (heterosis) of the MBL2-variant alleles has been proposed [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. The high frequency of MBL-variant alleles in different populations indicates that these polymorphisms represent a balanced genetic system favoring variant alleles arising from genetic selection. Thus, the normal A allele may confer disadvantages to the host under some circumstances, such as sepsis [<xref ref-type="bibr" rid="B34">34</xref>]. Although heterozygosity associated with a low MBL level showed an advantage for severity in the sepsis, there was no demonstrable influence on outcome. Accordingly, MBL polymorphisms may play a key role in the severity of sepsis, but they are not a determinant of the outcome.</p><p>In contrast, the serum MBL level in response to sepsis seems to be related to the outcome. A MBL level of 1.3 &#x003bc;g/mL or more was an independent factor in the survival of septic shock. However, among patients with the same haplotypes, the serum MBL level was different depending on the clinical setting. This suggests that other factors, such as cytokine levels or other alleles moving in tight linkage disequilibrium, may affect the level of MBL during sepsis. These findings may help explain why, despite the strong relation between <italic>MBL2 </italic>genetic variants and susceptibility to septic shock, there is no evidence to date showing the influence of the <italic>MBL2 </italic>genotype on clinical outcome.</p><p>Using <italic>MBL2 </italic>genotype analysis, several studies have shown variations in ethnic-specific genetic structure as well as non-genetic factors [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. However, the observation that a deficiency in the amount of functional MBL increases the severity of sepsis has been made repeatedly [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Therefore, measuring the serum MBL level may be important for the prognosis of septic patients in a clinical setting.</p><p>There were certain limitations to the present study. It has been reported that two promoter polymorphisms -550 and -221, and coding variants at codon 52, 54, and 57 of the MBL gene affect the MBL protein level in various populations. In more than 100 Korean controls, the codon 52 and 57 polymorphisms were not present and the effect of the -550 promoter SNP on MBL levels was stronger than that of the -221 promoter SNP. The effect of the X allele at -221 did not reach statistical significance (<italic>P </italic>= 0.156) in the correlation between MBL genotypes and MBL serum levels [<xref ref-type="bibr" rid="B23">23</xref>]. This could be because of the low frequency of the X allele in Koreans, 0.11, compared with 0.195 in the Danish population. As we screened only three known polymorphisms based on these results, we cannot rule out the possibility that the observed differences in MBL concentration are at least partially under the influence of additional polymorphisms. In addition, without examining family samples for inheritance patterns, the accuracy of this method of inference is unknown.</p><p>Another limitation of our study was that we did not evaluate patients without sepsis, such as patients with noninfectious systemic inflammatory response syndrome. If we had included patients with noninfectious systemic inflammatory response syndrome, we may have been able to explain our results more clearly and provide more support for the suggestion that there is an association of the homozygous <italic>MBL2 </italic>structural genotype (<italic>A/A</italic>) and the -550 genotype (<italic>H/H</italic>) with the progression from severe sepsis to septic shock. However, there were very few patients without infection or with sepsis without organ failure admitted to the medical ICU of the tertiary referral hospital.</p><p>Moreover, we measured MBL levels only once within the initial 24 hours of the septic course. This single measurement may reduce the power of the MBL level in terms of a prognostic factor. In addition, certain confounding factors, such as treatment and duration of illness before admission to the ICU, were not included in our analysis.</p></sec><sec><title>Conclusions</title><p>Our results showed that the genotype and serum level for <italic>MBL2 </italic>may have different clinical implications, and suggest that the patient with high <italic>MBL2 </italic>production responding to a bacterial invasion may have better prognosis irrespective of <italic>MBL2 </italic>gene polymorphism.</p></sec><sec><title>Key messages</title><p>&#x02022; Homozygosity for the <italic>MBL2 </italic>structural genotype (<italic>A/A</italic>) and the -550 genotype (<italic>H/H</italic>) was associated with the progression from severe sepsis to septic shock.</p><p>&#x02022; An MBL level of 1.3 &#x003bc;g/mL or more showed significantly lower 28-day mortality (<italic>P </italic>= 0.020; hazard ratio, 0.571; 95% CI, 0.355 to 0.916) in the septic shock group.</p><p>&#x02022; The genotype and serum level for <italic>MBL2 </italic>may have different clinical implications.</p></sec><sec><title>Abbreviations</title><p>APACHE: Acute Physiology and Chronic Health Evaluation; bp: base pair; CI: confidence interval; ELISA: enzyme-linked immunosorbent assay; ICU: intensive care unit; IQR: interquartile range; MASP: MBL-associated serine proteases; MBL: mannose-binding lectin; M:F: male;female; OR: odds ratio; PCR: polymerase chain reaction; ROC: receiver operator characteristic; SNP: single nucleotide polymorphism; SOFA: Sequential Organ Failure Assessment; TNF: tumor necrosis factor.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>HJW and KYS initiated the study. LCM and HSB participated in patient management. HJW, SKY and YJS analyzed the data. All the authors contributed to read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Word file containing a table that lists the Criteria of sepsis, severe sepsis, and septic shock used in our research.</p></caption><media xlink:href="cc8157-S1.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>Word file containing a table that lists the Hardy-Weinberg-test for the study population (healthy controls and septic patients).</p></caption><media xlink:href="cc8157-S2.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>We thank YY Park and EM Jo for technical expertise and assistance and JY Lim for data management.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Wax</surname><given-names>RS</given-names></name><article-title>Epidemiology of sepsis: an update</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><fpage>S109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1097/00003246-200107001-00035</pub-id><pub-id pub-id-type="pmid">11445744</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><article-title>Genetic dissection of the molecular pathogenesis of severe infection</article-title><source>Intensive Care Med</source><year>2000</year><volume>26</volume><fpage>S89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1007/s001340051124</pub-id><pub-id pub-id-type="pmid">10786964</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Sorensen</surname><given-names>TI</given-names></name><name><surname>Nielsen</surname><given-names>GG</given-names></name><name><surname>Andersen</surname><given-names>PK</given-names></name><name><surname>Teasdale</surname><given-names>TW</given-names></name><article-title>Genetic and environmental influences on premature death in adult adoptees</article-title><source>N Engl J Med</source><year>1988</year><volume>318</volume><fpage>727</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">3347221</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Allsopp</surname><given-names>CE</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Anstey</surname><given-names>NM</given-names></name><name><surname>Twumasi</surname><given-names>P</given-names></name><name><surname>Rowe</surname><given-names>PA</given-names></name><name><surname>Bennett</surname><given-names>S</given-names></name><name><surname>Brewster</surname><given-names>D</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><article-title>Common west African HLA antigens are associated with protection from severe malaria</article-title><source>Nature</source><year>1991</year><volume>352</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1038/352595a0</pub-id><pub-id pub-id-type="pmid">1865923</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Mira</surname><given-names>JP</given-names></name><name><surname>Cariou</surname><given-names>A</given-names></name><name><surname>Grall</surname><given-names>F</given-names></name><name><surname>Delclaux</surname><given-names>C</given-names></name><name><surname>Losser</surname><given-names>MR</given-names></name><name><surname>Heshmati</surname><given-names>F</given-names></name><name><surname>Cheval</surname><given-names>C</given-names></name><name><surname>Monchi</surname><given-names>M</given-names></name><name><surname>Teboul</surname><given-names>JL</given-names></name><name><surname>Rich&#x000e9;</surname><given-names>F</given-names></name><name><surname>Leleu</surname><given-names>G</given-names></name><name><surname>Arbibe</surname><given-names>L</given-names></name><name><surname>Mignon</surname><given-names>A</given-names></name><name><surname>Delpech</surname><given-names>M</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><article-title>Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study</article-title><source>JAMA</source><year>1999</year><volume>282</volume><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1001/jama.282.6.561</pub-id><pub-id pub-id-type="pmid">10450718</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Arnalich</surname><given-names>F</given-names></name><name><surname>Lopez-Maderuelo</surname><given-names>D</given-names></name><name><surname>Codoceo</surname><given-names>R</given-names></name><name><surname>Lopez</surname><given-names>J</given-names></name><name><surname>Solis-Garrido</surname><given-names>LM</given-names></name><name><surname>Capiscol</surname><given-names>C</given-names></name><name><surname>Fernandez-Capitan</surname><given-names>C</given-names></name><name><surname>Madero</surname><given-names>R</given-names></name><name><surname>Montiel</surname><given-names>C</given-names></name><article-title>Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis</article-title><source>Clin Exp Immunol</source><year>2002</year><volume>127</volume><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2002.01743.x</pub-id><pub-id pub-id-type="pmid">11876758</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>CL</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><article-title>Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy</article-title><source>Chest</source><year>2003</year><volume>124</volume><fpage>1103</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1378/chest.124.3.1103</pub-id><pub-id pub-id-type="pmid">12970043</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>De Maio</surname><given-names>A</given-names></name><name><surname>Torres</surname><given-names>MB</given-names></name><name><surname>Reeves</surname><given-names>RH</given-names></name><article-title>Genetic determinants influencing the response to injury, inflammation, and sepsis</article-title><source>Shock</source><year>2005</year><volume>23</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000144134.03598.c5</pub-id><pub-id pub-id-type="pmid">15614125</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Turner</surname><given-names>MW</given-names></name><name><surname>Hamvas</surname><given-names>RM</given-names></name><article-title>Mannose-binding lectin: structure, function, genetics and disease associations</article-title><source>Rev Immunogenet</source><year>2000</year><volume>2</volume><fpage>305</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">11256742</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Moine</surname><given-names>P</given-names></name><name><surname>Abraham</surname><given-names>E</given-names></name><article-title>Immunomodulation and sepsis: impact of the pathogen</article-title><source>Shock</source><year>2004</year><volume>22</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000140663.80530.73</pub-id><pub-id pub-id-type="pmid">15377883</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Martins</surname><given-names>PS</given-names></name><name><surname>Brunialti</surname><given-names>MK</given-names></name><name><surname>da Luz Fernandes</surname><given-names>M</given-names></name><name><surname>Martos</surname><given-names>LS</given-names></name><name><surname>Gomes</surname><given-names>NE</given-names></name><name><surname>Rigato</surname><given-names>O</given-names></name><name><surname>Salomao</surname><given-names>R</given-names></name><article-title>Bacterial recognition and induced cell activation in sepsis</article-title><source>Endocr Metab Immune Disord Drug Targets</source><year>2006</year><volume>6</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">16787293</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><article-title>The lectin-complement pathway--its role in innate immunity and evolution</article-title><source>Immunol Rev</source><year>2004</year><volume>198</volume><fpage>185</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.0123.x</pub-id><pub-id pub-id-type="pmid">15199963</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Larsen</surname><given-names>F</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><article-title>Mannose-binding lectin deficiency--revisited</article-title><source>Mol Immunol</source><year>2003</year><volume>40</volume><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/S0161-5890(03)00104-4</pub-id><pub-id pub-id-type="pmid">12914814</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Turner</surname><given-names>MW</given-names></name><article-title>The role of mannose-binding lectin in health and disease</article-title><source>Mol Immunol</source><year>2003</year><volume>40</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S0161-5890(03)00155-X</pub-id><pub-id pub-id-type="pmid">14568388</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Melbye</surname><given-names>M</given-names></name><name><surname>Sorensen</surname><given-names>P</given-names></name><name><surname>Homoe</surname><given-names>P</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Molbak</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>CH</given-names></name><name><surname>Andersen</surname><given-names>LH</given-names></name><name><surname>Hahn</surname><given-names>GW</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name><article-title>Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>1316</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1001/jama.285.10.1316</pub-id><pub-id pub-id-type="pmid">11255386</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Kakkanaiah</surname><given-names>VN</given-names></name><name><surname>Shen</surname><given-names>GQ</given-names></name><name><surname>Ojo-Amaize</surname><given-names>EA</given-names></name><name><surname>Peter</surname><given-names>JB</given-names></name><article-title>Association of low concentrations of serum mannose-binding protein with recurrent infections in adults</article-title><source>Clin Diagn Lab Immunol</source><year>1998</year><volume>5</volume><fpage>319</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">9605984</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Summerfield</surname><given-names>JA</given-names></name><name><surname>Ryder</surname><given-names>S</given-names></name><name><surname>Sumiya</surname><given-names>M</given-names></name><name><surname>Thursz</surname><given-names>M</given-names></name><name><surname>Gorchein</surname><given-names>A</given-names></name><name><surname>Monteil</surname><given-names>MA</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name><article-title>Mannose binding protein gene mutations associated with unusual and severe infections in adults</article-title><source>Lancet</source><year>1995</year><volume>345</volume><fpage>886</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)90009-8</pub-id><pub-id pub-id-type="pmid">7707811</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Sumiya</surname><given-names>M</given-names></name><name><surname>Super</surname><given-names>M</given-names></name><name><surname>Tabona</surname><given-names>P</given-names></name><name><surname>Levinsky</surname><given-names>RJ</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name><name><surname>Summerfield</surname><given-names>JA</given-names></name><article-title>Molecular basis of opsonic defect in immunodeficient children</article-title><source>Lancet</source><year>1991</year><volume>337</volume><fpage>1569</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(91)93263-9</pub-id><pub-id pub-id-type="pmid">1675710</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Lipscombe</surname><given-names>RJ</given-names></name><name><surname>Sumiya</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Lau</surname><given-names>YL</given-names></name><name><surname>Levinsky</surname><given-names>RJ</given-names></name><name><surname>Summerfield</surname><given-names>JA</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name><article-title>High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene</article-title><source>Hum Mol Genet</source><year>1992</year><volume>1</volume><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1093/hmg/1.9.709</pub-id><pub-id pub-id-type="pmid">1304173</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Kurtzhals</surname><given-names>JA</given-names></name><name><surname>Lamm</surname><given-names>LU</given-names></name><name><surname>Ryder</surname><given-names>LP</given-names></name><name><surname>Thiel</surname><given-names>S</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name><article-title>A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein</article-title><source>Immunogenetics</source><year>1994</year><volume>40</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/BF00163962</pub-id><pub-id pub-id-type="pmid">8206524</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Waheed</surname><given-names>U</given-names></name><name><surname>Hansen</surname><given-names>TK</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Garrard</surname><given-names>CS</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name><name><surname>Klein</surname><given-names>NJ</given-names></name><name><surname>Brett</surname><given-names>SJ</given-names></name><name><surname>Hinds</surname><given-names>CJ</given-names></name><article-title>Mannose-binding lectin polymorphisms in severe sepsis: relationship to levels, incidence, and outcome</article-title><source>Shock</source><year>2006</year><volume>25</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000186928.57109.8d</pub-id><pub-id pub-id-type="pmid">16369192</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Thiel</surname><given-names>S</given-names></name><name><surname>Kurtzhals</surname><given-names>JA</given-names></name><name><surname>Lamm</surname><given-names>LU</given-names></name><name><surname>Ryder</surname><given-names>LP</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name><article-title>Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><fpage>3013</fpage><lpage>3020</lpage><pub-id pub-id-type="pmid">7673719</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Yum</surname><given-names>JS</given-names></name><name><surname>Moon</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Yang</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>HL</given-names></name><name><surname>Yoon</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><article-title>Analysis of mannose-binding lectin 2 (MBL2) genotype and the serum protein levels in the Korean population</article-title><source>Mol Immunol</source><year>2005</year><volume>42</volume><fpage>969</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2004.09.036</pub-id><pub-id pub-id-type="pmid">15829288</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Cerra</surname><given-names>FB</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Fein</surname><given-names>AM</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Schein</surname><given-names>RM</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name><article-title>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine</article-title><source>Chest</source><year>1992</year><volume>101</volume><fpage>1644</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1378/chest.101.6.1644</pub-id><pub-id pub-id-type="pmid">1303622</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>I</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><article-title>Characterization of publicly available SNPs in the Korean population</article-title><source>Hum Mutat</source><year>2001</year><volume>17</volume><fpage>281</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1002/humu.24</pub-id><pub-id pub-id-type="pmid">11295825</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="book"><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Roessli</surname><given-names>D</given-names></name><name><surname>Excoffier</surname><given-names>L</given-names></name><source>Arlequin: A Software of Population Genetics Data Analysis Version 2.000</source><year>2000</year><publisher-name>Genetics and Biometry Laboratory, Department of Arthropology, University of Geneva</publisher-name></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>J</surname><given-names>JS</given-names></name><name><surname>Quist</surname><given-names>L</given-names></name><name><surname>Taaning</surname><given-names>E</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><article-title>Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome</article-title><source>J Infect Dis</source><year>2003</year><volume>188</volume><fpage>1394</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1086/379044</pub-id><pub-id pub-id-type="pmid">14593599</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Balslev</surname><given-names>U</given-names></name><name><surname>Hofmann</surname><given-names>B</given-names></name><name><surname>Pedersen</surname><given-names>C</given-names></name><name><surname>Gerstoft</surname><given-names>J</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name><article-title>Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>236</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)08440-1</pub-id><pub-id pub-id-type="pmid">9014910</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Pressler</surname><given-names>T</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Frederiksen</surname><given-names>B</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name><name><surname>Hoiby</surname><given-names>N</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><article-title>Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1172/JCI6861</pub-id><pub-id pub-id-type="pmid">10449435</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Fidler</surname><given-names>KJ</given-names></name><name><surname>Wilson</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>JC</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name><name><surname>Peters</surname><given-names>MJ</given-names></name><name><surname>Klein</surname><given-names>NJ</given-names></name><article-title>Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><fpage>1438</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1007/s00134-004-2303-8</pub-id><pub-id pub-id-type="pmid">15127191</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Steffensen</surname><given-names>R</given-names></name><name><surname>Thiel</surname><given-names>S</given-names></name><name><surname>Varming</surname><given-names>K</given-names></name><name><surname>Jersild</surname><given-names>C</given-names></name><name><surname>Jensenius</surname><given-names>JC</given-names></name><article-title>Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers</article-title><source>J Immunol Methods</source><year>2000</year><volume>241</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/S0022-1759(00)00198-8</pub-id><pub-id pub-id-type="pmid">10915847</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Lipscombe</surname><given-names>RJ</given-names></name><name><surname>Sumiya</surname><given-names>M</given-names></name><name><surname>Summerfield</surname><given-names>JA</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name><article-title>Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype</article-title><source>Immunology</source><year>1995</year><volume>85</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">7558163</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Hellemann</surname><given-names>D</given-names></name><name><surname>Larsson</surname><given-names>A</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Bonde</surname><given-names>J</given-names></name><name><surname>Jarlov</surname><given-names>JO</given-names></name><name><surname>Wiis</surname><given-names>J</given-names></name><name><surname>Faber</surname><given-names>T</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name><article-title>Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients</article-title><source>Hum Mol Genet</source><year>2007</year><volume>16</volume><fpage>3071</fpage><lpage>3080</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm265</pub-id><pub-id pub-id-type="pmid">17872904</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Harboe</surname><given-names>M</given-names></name><name><surname>Oettinger</surname><given-names>T</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name><article-title>Dual role of mannan-binding protein in infections: another case of heterosis?</article-title><source>Eur J Immunogenet</source><year>1994</year><volume>21</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1111/j.1744-313X.1994.tb00183.x</pub-id><pub-id pub-id-type="pmid">9098426</pub-id></mixed-citation></ref></ref-list></back></article>